Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: Free Radic Biol Med. 2018 Dec 19;131:332–344. doi: 10.1016/j.freeradbiomed.2018.12.023

Figure 7.

Figure 7.

The animated metabolite, 4'-NH2-EGCG, retains the bioactivity of EGCG. (A) Growth inhibition of EGCG and 4'-NH2-EGCG against human colon cancer cells HCT-116 and HT-29. MTT assays: cells were treated with 0, 20, 40, 60, 80, and 100 μM concentrations of the test compounds for 48 h in the presence of 10% FBS and 1% streptomycin/penicillin at 37 °C. Bar, standard error (n = 6). (B) Anti-inflammatory effects of EGCG and 4'-NH2-EGCG in murine RAW 264.7 macrophages. RAW 264.7 cells were pretreated with different doses of EGCG and 4'-NH2-EGCG for 1 h and then with 100 ng/mL of LPS with different concentrations of EGCG and 4'-NH2-EGCG for another 23 h. The production of NO was assayed in the culture medium using Griess reagent. (C) the expression of iNOS was detected by Western blot. Quantification of iNOS was normalized to β-actin. These experiments were repeated three times with similar results. The values are expressed as means ± standard deviation. (*) p < 0.05, (**) p < 0.01, (***) p < 0.001 indicate statistically significant differences from the LPS-treated group.